Oxytocin plus antibiotics: A synergism of potentiation to enhance bovine uterine contractility

This in vitro study investigates the modulatory effect of three antibiotics (amoxicillin, enrofloxacin, and rifaximin) on contractility of the bovine uterine tissue, in follicular and luteal phases. The evaluation of the effects of these antibiotics (104 M) was performed on oxytocin-induced contractility. The decision to test these antibiotics with the oxytocin (106 M) comes from the reported ability of these combinations of hinder the antibiotic resistance and the formation of bacterial biofilms. The procedures were carried out in isolated organ bath, and the contractile functionality of the strip throughout the experiment was evaluated after a dose of carbachol (105 M). The results demonstrate the different modulatory activity of these antibiotics, on the plateau of contraction induced by oxytocin, in both phases of the estrus cycle. The differing individual antibiotic effects of our testing made it possible to identify, only in some cases. Rifaximin in the follicular phase and enrofloxacin in both phases of the estrous cycle, induced a synergistic enhancement (potentiation) of uterine strip contraction induced by oxytocin. This result is thought important because these associations might enable, in vivo, a simultaneous increase of uterine cleaning and the antimicrobial action on bacteria in planktonic form and of those organized in biofilms

A first-in-human clinical study of a new SP-B and SP-C enriched synthetic surfactant (CHF5633) in preterm babies with respiratory distress syndrome: two-year outcomes

Objective: To assess at 24 months corrected age (CA) the neurological, respiratory, and general health status of children born prematurely from 27 +0 to 33 +6 weeks’ gestation who were treated in a first-in-human study with a new fully synthetic surfactant (CHF5633) enriched with SP-B and SP-C proteins.  Outcome measures: Children were assessed using Bayley Scales of Infant Development (BSID), with a score below normal defined as BSID-II Mental Development Index score <70, or BSID-III cognitive composite score <85. In addition, a health status questionnaire was used to check for functional disability including respiratory problems and related treatments, sensory and neurodevelopment assessments, communication skills as well as the number of hospitalizations.  Results: 35 of 39 survivors had a neurodevelopmental assessment, 24 infants being evaluated by Bayley’s Scales and 11 by health status questionnaires only. 23 children had scores within normal limits and one had BSID-III <85. The remaining 11 were judged clinically to have normal development. Health status questionnaires detected only issues that would normally be expected in preterm-born children.  Conclusions: This assessment offers reassurance that treatment with CHF5633 surfactant was not associated with adverse neurodevelopmental, respiratory, or health outcomes by two years corrected age

A first-in-human clinical study of a new SP-B and SP-C enriched synthetic surfactant (CHF5633) in preterm babies with respiratory distress syndrome

Objective CHF5633 (Chiesi Farmaceutici S.p.A., Parma, Italy) is the first fully synthetic surfactant enriched by peptide analogues of two human surfactant proteins. We planned to assess safety and tolerability of CHF5633 and explore preliminary efficacy. Design Multicentre cohort study. Patients Forty infants from 27+0 to 33+6 weeks gestation with respiratory distress syndrome requiring fraction of inspired oxygen (FiO2) ≥0.35 were treated with a single dose of CHF5633 within 48 hours after birth. The first 20 received 100 mg/kg and the second 20 received 200 mg/kg. Outcome measures Adverse events (AEs) and adverse drug reactions (ADRs) were monitored with complications of prematurity considered AEs if occurring after dosing. Systemic absorption and immunogenicity were assessed. Efficacy was assessed by change in FiO2 after dosing and need for poractant-alfa rescue. Results Rapid and sustained improvements in FiO2 were observed in 39 (98%) infants. One responded neither to CHF5633 nor two poractant-alfa doses. A total of 79 AEs were experienced by 19 infants in the 100 mg/kg cohort and 53 AEs by 20 infants in the 200 mg/kg cohort. Most AEs were expected complications of prematurity. Two unrelated serious AEs occurred in the second cohort. One infant died of necrotising enterocolitis and another developed viral bronchiolitis after discharge. The single ADR was an episode of transient endotracheal tube obstruction following a 200 mg/kg dose. Neither systemic absorption, nor antibody development to either peptide was detected. Conclusions Both CHF5633 doses were well tolerated and showed promising clinical efficacy profile. These encouraging data provide a basis for ongoing randomised controlled trials

Effect of neostigmine on contractility of equine pre-ovulatory follicles: an in vitro study.

In this study, the Authors investigated the modulatory effect of three single doses (106, 105, and 104 M) of neostigmine on the spontaneous contractility of equine pre-ovulatory follicles in an isolated organ bath, to establish the relationship between this acetylcholinesterase inhibitor and ovulation, in the mare. The results indicate that neostigmine increases pre-ovulatory contractility in equine follicles at each dose, but in a different manner. Indeed, the rise in contractility induced by neostigmine at 106 M and 104 M was phasic, while at 105 M it was tonic. The data obtained indicate possible implications of these drugs in the pharmacological modulation of equine ovulation

2.4-W intracavity doubled cw Nd:GdVO4 laser at 670 nm

Intracavity second harmonic generation with diode-pumped Nd:GdVO4 laser and LBO nonlinear crystal yielded as much as 2.4 W in a TEM00 mode at 671 nm, with a very compact resonator. The laser is highly efficient and low-noise

Lidocaine decreases the xylazine-evoked contractility in pregnant cows

The objective of this in vitro study was to evaluate and compare the effects of xylazine on basal uterine contractility of bovine pregnant uterine strips and that of lidocaine on xylazine-sensitized bovine pregnant uterine strips, at different stages of pregnancy. Basal contractility was evaluated in an isolated organ bath and the functionality of the strips throughout the experiment was evaluated using a dose of carbachol (10−5 M). Uterine motility, expressed with amplitude, frequency of contractions as well as the area under the curve, was recorded in different stages of pregnancy and data were collected at 15-min intervals (5-min before and 5-min after xylazine administration and 5-min after lidocaine addition on the plateau contraction induced by xylazine). Uterine motility increased in all the stages of pregnancy after xylazine addition and gradually decreased after treatment with lidocaine. These data suggest that lidocaine might decrease the tonic effect induced by xylazine on bovine pregnant uteri

High-brightness 2.4-W continuous-wave Nd:GdVO4 laser at 670 nm

We report on a diode-pumped 1.3-mm Nd:GdVO4 cw laser, intracavity doubled for highly efficient generation of red light. We obtained as much as 2.4 W of power at 670 nm (corresponding to 26% optical-to-optical efficiency) in a nearly TEM00 mode and with small amplitude noise. To the best of our knowledge, these results represent the highest performance at this wavelength for cw solid-state lasers

FLUOROQUINOLONE AND OVARIECTOMY IN THE BITCH: PHYSIOLOGY OF THE IMMUNE SYSTEM AS TO CD56 AND CD16 EXPRESSION

Natural killer (NK) cells are innate lymphoid cells which act against a variety of pathogens and tumours. Phenotypically they are characterized by surface markers named cluster designation (CD) antigens. CD56 and CD16 are recognized as specific NK markers in the dogs as well as in humans. Surgical interventions suppress NK cells both in rats and humans. In this direction, it has been shown that an antibiotic regimen (amoxicillin, benzylpenicillin/dihydrostreptomycin, sulfametazine/sulfamerazine/ sulfathiazole, enrofloxacin, lincomycin/spectinomycin) administered only twice is effective in preventing infections after laparatomic ovariectomy, in the bitch. On these grounds, this research will show that the administration of a fluoroquinolone (5 mg/kg of enrofloxacin, Baytril®, Bayer, Milan, Italy) one hour before and at the end of ovariectomy is able to increase CD56 and CD16 expression levels. Moreover, the antibiotic administration modifies the relative expression levels of the two CD; thus suggesting that the fluoroquinolone employed enhances the activation of a specific subset of NK cells mainly involved in body recovering during the post operative period as already observed in humans

Effects of d-cloprostenol on different layers and regions of the bovine uterus during the follicular and luteal phases.

Introduction: D-cloprostenol is a synthetic PGF2a, commonly used in bovine reproduction, that increases myometral contractility. However, little is known regarding its contractile behaviour and how it depends on the reproductive state and uterine topography (regions and muscular layers). Hypothesis and objectives: These aspects would affect the action of d-cloprostenol on the uterus. Therefore, we hypothesize a possible use of this drug at the time of artificial insemination, to improve conception rates and, in the post-partum, in order to accelerate uterine involution in dairy cattle. The purpose of the present study was to investigates the modulatory effect of d-cloprostenol on contractility of the bovine uterine region (horn and corpus) and their muscle layers (circular and longitudinal), in follicular and luteal phases. To our knowledge, motility effects of d-cloprostenol on different regions from healthy bovine uterus have not been described up to now. Materials and methods: Uterine specimens were collected from uterine body and horn of cattle in the follicular (n ¼ 28) and luteal phase (n ¼ 32) of the estrous cycle at slaughter. Two strips were prepared from each regions corresponding to the circular and the longitudinal muscular layers, respectively. Samples were cultured in an organ bath, exposed to synthetic prostaglandin (1 mM d-cloprostenol) and their contractile activity was monitored for 10 min. The functionality of the strip throughout the experiment was tested by a dose of carbachol (105 M). Results: The mean basal amplitude of contractions was higher in the follicular compared to the luteal phase in uterine horn samples, but not in muscles collected from the uterine body. The amplitude of contractions increased after d-cloprostenol administration in all tissues with a greater increase in samples from cattle in the follicular phase. The frequency of contractions increased after d-cloprostenol administration in longitudinal but not in circular fibrees. Conclusion: The contractile responses to d-cloprostenol in both horn and corpus were strongest in the circular muscles but weak in the longitudinal muscles